Today's signal
Matthew Gallagher built a $1.8 billion company from his LA home with $20,000, AI tools, and one employee — his brother. His startup Medvi, a GLP-1 telehealth provider, launched in September 2024, hit $401 million in sales in its first full year, and is on track for $1.8 billion in 2026. The New York Times verified the financials.
Why it matters
Sam Altman had a betting pool for when this would happen. Dario Amodei said 2026. Gallagher used AI to write his platform's code, produce website copy, generate ad content, handle customer service, and analyze business performance in real time — outsourcing only the regulated parts like doctors, pharmacies, and shipping to partners CareValidate and OpenLoop Health. No VC. No team. No office. The playbook just got rewritten.
The take
The critics say it's the GLP-1 market, not the AI. They're half right — and that's exactly the point. Gallagher didn't invent the drug. He built the machine around it, alone, in two months. Hims and Hers needs 2,400 employees and posts a 5.5% net margin. Medvi has two people and a 16.2% margin. The one-person company isn't coming. It just filed its taxes.
The number
$65 million — Medvi's net profit in 2025, from $401 million in revenue, with two employees (Matthew and his brother, who came on board at a later stage). Total capital invested to start: $20,000.